{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2173.055","value":"2354.03"},{"groupId":"OG001","spread":"1352.707","value":"1927.77"},{"groupId":"OG002","spread":"1533.622","value":"1853.84"},{"groupId":"OG003","spread":"1831.099","value":"2129.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"47"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1253.715","value":"2037.90"},{"groupId":"OG001","spread":"357.010","value":"1331.17"},{"groupId":"OG002","spread":"688.722","value":"643.00"},{"groupId":"OG003","spread":"1068.270","value":"1647.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"18"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"763.348","value":"2225.00"},{"groupId":"OG001","spread":"705.280","value":"2058.00"},{"groupId":"OG002","spread":"487.904","value":"1585.00"},{"groupId":"OG003","spread":"672.891","value":"2032.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"11"}],"units":"Participants"}],"title":"Cycle 4 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"47"}],"units":"Participants"}],"description":"Plasma were collected for trough level PK analysis of rucaparib 1 hour before the morning dose on Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1.","dispersionType":"Standard Deviation","groups":[{"description":"Patients with HRD status unknown who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor genome-wide LOH was not tested or not determined were considered HRD unknown.","id":"OG000","title":"HRD Unknown"},{"description":"Patients with HRD status negative who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor had genome-wide LOH \\< 10% were considered HRD-negative.","id":"OG001","title":"HRD Negative"},{"description":"Patients with HRD status positive who received continuous dosing with rucaparib 600 mg twice a day (BID) in 28-day cycles. Patients whose tumor had genome-wide LOH ≥ 10% were considered HRD-positive.","id":"OG002","title":"HRD Positive"},{"description":"All patients","id":"OG003","title":"Overall"}],"paramType":"MEAN","populationDescription":"Safety population - all patients who received at least 1 dose of rucaparib and who had at least 1 PK sample collected. The number analyzed at each timepoint includes only those participants who remained on study and with viable samples collected at that timepoint.","reportingStatus":"POSTED","timeFrame":"From Cycle 2 Day 1 to Cycle 4 Day 1, or approximately 2 months","title":"Pharmacokinetics - Trough (Cmin) Level Rucaparib Concentrations","type":"SECONDARY","unitOfMeasure":"ng/mL"}